HHV8
MCID: KPS004
MIFTS: 72

Kaposi Sarcoma (HHV8)

Categories: Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 57 11 19 58 75 28 53 5 41 14 71 31
Kaposi's Sarcoma 11 19 14 16 75
Kaposi's Sarcoma-Associated Herpesvirus 11 75
Kaposi Sarcoma, Susceptibility to 57 12
Kaposi's Sarcoma of Soft Tissue 11 71
Kaposi's Sarcoma of Palate 11 71
Kaposi's Sarcoma of Lung 11 71
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 57
Multiple Idiopathic Pigmented Hemangiosarcoma 57
Kaposi's Sarcoma of Central Nervous System 11
Kaposi's Sarcoma of Gastrointestinal Sites 11
African Lymphadenopathic Kaposi's Sarcoma 11
Central Nervous System Kaposi's Sarcoma 11
Angiofollicular Ganglionic Hyperplasia 71
Kaposi's Sarcoma of the Gallbladder 11
Sarcoma, Kaposi, Susceptibility to 38
Lymphadenopathic Kaposi's Sarcoma 11
Multi-Centric Castleman's Disease 71
Kaposi's Sarcoma of Soft Tissues 11
Kaposi's Sarcoma of the Prostate 11
Kaposi's Sarcoma of Conjunctiva 11
Kaposi's Sarcoma of Lymph Nodes 11
Non Aids Related Kaposi Sarcoma 19
Non-Aids-Related Kaposi Sarcoma 71
Conjunctival Kaposi's Sarcoma 11
Kaposi's Sarcoma of Esophagus 11
Gallbladder Kaposi's Sarcoma 11
Soft Tissue Kaposi's Sarcoma 11
Mediterranean Kaposi Sarcoma 19
Esophageal Kaposi's Sarcoma 11
Intestinal Kaposi's Sarcoma 11
Kaposi's Sarcoma of the Cns 11
Lymph Node Kaposi's Sarcoma 11
Cutaneous Kaposi's Sarcoma 11
Kaposi's Sarcoma of Cornea 11
Pulmonary Kaposi's Sarcoma 11
Kaposi Sarcoma Herpesvirus 19
Kaposi's Sarcoma of Heart 11
Kaposi's Sarcoma of Penis 11
Prostate Kaposi's Sarcoma 11
Angiolymphoid Hyperplasia 71
Cardiac Kaposi's Sarcoma 11
Corneal Kaposi's Sarcoma 11
Gastric Kaposi's Sarcoma 11
Kaposi's Sarcoma of Anus 11
Kaposi's Sarcoma of Skin 11
Palate Kaposi's Sarcoma 11
Kaposi's Sarcoma, Lung 11
Kaposi's Sarcoma, Skin 11
Penis Kaposi's Sarcoma 11
Anal Kaposi's Sarcoma 11
Human Herpesvirus 8 19
Sarcoma, Kaposi 43
Hhv8 19
Kshv 19

Characteristics:


Inheritance:

Autosomal dominant 57

Prevelance:

1-9/1000000 (Europe, Croatia, Ireland, Latvia, Lithuania, Malta, Portugal, Spain, Switzerland, Netherlands, United Kingdom) 1-9/100000 (Europe, Europe, Iceland, Italy) <1/1000000 (Austria, Belgium, Bulgaria, Czech Republic, Estonia, Finland, Germany, Norway, Poland, Slovakia, Slovenia) 58

Age Of Onset:

Adult 58

Age Of Death:

adult 58

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 11 DOID:8632
OMIM® 57 148000
MeSH 43 D012514
MESH via Orphanet 44 D012514
ICD10 via Orphanet 32 C46.0 C46.1 C46.2 more
UMLS via Orphanet 72 C0036220
Orphanet 58 ORPHA33276
MedGen 40 C3538945
UMLS 71 C0017531 C0036220 C0153560 more

Summaries for Kaposi Sarcoma

GARD: 19 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS).

MalaCards based summary: Kaposi Sarcoma, also known as kaposi's sarcoma, is related to sarcoma and acquired immunodeficiency syndrome, and has symptoms including exanthema, pruritus and fever. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Bleomycin and Lopinavir have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and lymph node, and related phenotypes are recurrent herpes and neoplasm of the skin

MedlinePlus: 41 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in: People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS medicines. NIH: National Cancer Institute

OMIM®: 57 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000) (Updated 24-Oct-2022)

Orphanet: 58 A rare vascular tumor that is characterized by human herpes virus 8 (HHV-8)-induced endothelial inflammatory neoplasm that develops with various clinically distinct settings, manifesting mostly as cutaneous lesions, or mucosal or visceral involvement.

Disease Ontology: 11 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

Wikipedia 75 Kaposi sarcoma: Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, in lymph nodes, in the... more...

Kaposi's sarcoma-associated herpesvirus: Kaposi's sarcoma-associated herpesvirus (KSHV) is the ninth known human herpesvirus; its formal name... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1055)
# Related Disease Score Top Affiliating Genes
1 sarcoma 32.6 TNFRSF4 STIM1 SLC7A11 IL6ST IL6 FGF4
2 acquired immunodeficiency syndrome 32.1 IL6 IL1B IFNA2 IFNA1
3 castleman disease 31.9 VEGFA IL6ST IL6R IL6
4 multicentric castleman disease 31.8 VEGFA IL6R IL6
5 immune deficiency disease 31.7 IL6R IL6 IL1B IFNA1 CCR8
6 neutropenia 31.1 IL6 IL1B IFNA2 IFNA1
7 viral infectious disease 31.1 IL6 IL1B IFNA2 IFNA1
8 inflammatory bowel disease 1 31.1 IL6-AS1 IL6 IL1B
9 vascular cancer 31.1 VEGFA IFNA2 FGF2
10 hemangioma 31.0 VEGFA IL6 IFNA2 FGF2
11 exanthem 30.9 VEGFA IL6 IL1B IFNA1
12 diarrhea 30.9 IL6 IL1B IFNA2 IFNA1
13 chickenpox 30.9 IL6 IL1B IFNA1
14 poems syndrome 30.8 VEGFA IL6 IL1B FGF2
15 splenomegaly 30.8 VEGFA IFNA2 IFNA1 ADA2
16 hepatitis a 30.8 IL1B IFNA2 IFNA1
17 intussusception 30.8 VEGFA IL6 FGF2
18 temporal arteritis 30.8 VEGFA IL6R IL6 IL1B
19 deficiency anemia 30.7 VEGFA IL6 IL1B IFNA2 IFNA1
20 lymphangioma 30.7 VEGFA IL6 IL1B
21 vasculitis 30.7 IL6 IL1B IFNA2 ADA2
22 respiratory failure 30.7 VEGFA IL6 IL1B IFNA1
23 anogenital venereal wart 30.6 IL6 IFNA2 IFNA1
24 thrombocytopenia 30.6 VEGFA STIM1 IL6 IL1B IFNA2 IFNA1
25 polyarteritis nodosa 30.6 IL6 IFNA2 ADA2
26 pericardial effusion 30.6 VEGFA IL6 FGF2
27 pleural disease 30.6 VEGFA IL6 IL1B
28 proteasome-associated autoinflammatory syndrome 1 30.6 IL6 IL1B IFNA1
29 rheumatoid arthritis 30.5 VEGFA TNFRSF4 OSM IL6ST IL6R IL6
30 periodontitis, chronic 30.5 IL6 IL1B
31 peripheral nervous system disease 30.5 VEGFA IL6 IL1B IFNA1 FGF2
32 dysentery 30.5 IL6 IL1B IFNA2
33 acute pericementitis 30.5 IL6 IL1B
34 central nervous system vasculitis 30.5 IL6R IL6 IL1B
35 osteosclerotic myeloma 30.4 VEGFA IL6 IL1B
36 necrotizing ulcerative gingivitis 30.4 IL6 IL1B
37 anterior uveitis 30.4 VEGFA IL6 IL1B
38 relapsing-remitting multiple sclerosis 30.4 IL6 IL1B IFNA1
39 kidney cancer 30.4 VEGFA IFNA2 IFNA1 FGF2
40 myeloma, multiple 30.4 VEGFA OSM IL6ST IL6R IL6 IL1B
41 lymphomatoid granulomatosis 30.4 IFNA2 IFNA1
42 severe acute respiratory syndrome 30.4 IL6 IL1B IFNA1
43 rheumatoid arthritis, systemic juvenile 30.4 IL6-AS1 IL6
44 cryoglobulinemia, familial mixed 30.4 IFNA2 IFNA1
45 uveitis 30.4 VEGFA IL6 IL1B IFNA2
46 common cold 30.3 IL6 IL1B IFNA2 IFNA1
47 gingivitis 30.3 VEGFA IL6 IL1B
48 intestinal benign neoplasm 30.3 VEGFA IL6 IL1B
49 stomatitis 30.3 IL6 IL1B IFNA2 IFNA1
50 cryoglobulinemia 30.3 IL6 IL1B IFNA2 IFNA1

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Human phenotypes related to Kaposi Sarcoma:

58 30 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent herpes 58 30 Obligate (100%) Obligate (100%)
HP:0005353
2 neoplasm of the skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008069
3 hypermelanotic macule 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001034
4 abnormality of the lower limb 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002814
5 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002721
6 hemangioma 58 30 Frequent (33%) Frequent (79-30%)
HP:0001028
7 abnormality of the spleen 58 30 Frequent (33%) Frequent (79-30%)
HP:0001743
8 abnormality of the gastrointestinal tract 58 30 Frequent (33%) Frequent (79-30%)
HP:0011024
9 papule 58 30 Frequent (33%) Frequent (79-30%)
HP:0200034
10 encephalopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0001298
11 skin nodule 58 30 Frequent (33%) Frequent (79-30%)
HP:0200036
12 generalized lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0008940
13 abnormal retinal morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0000479
14 lymphoproliferative disorder 58 30 Frequent (33%) Frequent (79-30%)
HP:0005523
15 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012378
16 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
17 lymphedema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001004
18 skin rash 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000988
19 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001824
20 abnormal lung morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002088
21 venous insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005293
22 abnormality of the liver 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001392
23 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002014
24 skin plaque 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200035
25 neoplasm 30 HP:0002664
26 macule 58 Very frequent (99-80%)
27 edema 30 HP:0000969
28 neoplasm by anatomical site 58 Occasional (29-5%)
29 kaposi's sarcoma 30 HP:0100726

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema

Clinical features from OMIM®:

148000 (Updated 24-Oct-2022)

UMLS symptoms related to Kaposi Sarcoma:


exanthema; pruritus; fever

MGI Mouse Phenotypes related to Kaposi Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.8 CASP7 CCL1 CCR8 CDK6 IFNA1 IFNA2
2 neoplasm MP:0002006 9.76 CDK6 FGF2 IL1B IL6 IL6R IL6ST
3 hematopoietic system MP:0005397 9.5 CASP7 CCL1 CDK6 FGF2 IFNA1 IFNA2

Drugs & Therapeutics for Kaposi Sarcoma

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
2
Lopinavir Approved Phase 4 192725-17-0 92727
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Nevirapine Approved Phase 4 129618-40-2 4463
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
7
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
9 Stavudine, lamivudine, nevirapine drug combination Phase 4
10 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
11 Calcineurin Inhibitors Phase 4
12
Daunorubicin Approved Phase 3 20830-81-3 30323
13
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5, 188062-50-2 441300
14
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
15
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
16
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
17 Dideoxynucleosides Phase 2, Phase 3
18 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20 Antimetabolites Phase 2, Phase 3
21 Antibodies, Monoclonal Phase 2, Phase 3
22 Antibodies Phase 2, Phase 3
23 Immunoglobulins, Intravenous Phase 2, Phase 3
24 Immunoglobulins Phase 2, Phase 3
25 Cc-486 Phase 2, Phase 3
26
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
27
Nelfinavir Approved Phase 2 159989-64-7 64143
28
Nicotine Approved Phase 2 54-11-5 942 89594
29
Indinavir Approved Phase 2 150378-17-9 5362440
30
Vinblastine Approved Phase 2 865-21-4 241903 13342
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
32
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
33
Etravirine Approved Phase 2 269055-15-4 193962
34
Tipranavir Approved, Investigational Phase 2 174484-41-4 65027 54682461
35
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
36
Alitretinoin Approved, Investigational Phase 2 5300-03-8 449171
37
Mitoxantrone Approved, Investigational Phase 2 70476-82-3, 65271-80-9 4212
38
Didanosine Approved Phase 2 69655-05-6 50599
39
Saquinavir Approved, Investigational Phase 2 127779-20-8 60787 441243
40
Cidofovir Approved Phase 2 113852-37-2 60613
41
Brentuximab vedotin Approved, Investigational Phase 1, Phase 2 914088-09-8
42
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
43
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
44
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
45
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
47
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
48
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
49
Altretamine Approved Phase 2 645-05-6 2123
50
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
4 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
5 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
6 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
7 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
8 Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
10 A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 Completed NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
11 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
12 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
13 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
14 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
16 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
17 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
18 A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings Not yet recruiting NCT05411237 Phase 3 Pegylated liposomal doxorubicin;Paclitaxel
19 A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements Suspended NCT04799275 Phase 2, Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
20 A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS) Unknown status NCT03219671 Phase 2 Nivolumab;Ipilimumab
21 Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique Unknown status NCT03469804 Phase 2 Pembrolizumab
22 Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART) Unknown status NCT00003419 Phase 2
23 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
24 A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma Completed NCT03077451 Phase 2 Nelfinavir Mesylate
25 A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
26 A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
27 A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV Completed NCT01495598 Phase 1, Phase 2 Pomalidomide
28 Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease Completed NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
29 Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial Completed NCT00295984 Phase 2 nicotine
30 Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality Completed NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
31 Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
32 An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
33 Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
34 A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma Completed NCT00362310 Phase 2 indinavir
35 Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma Completed NCT00055237 Phase 2
36 Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging. Completed NCT02201420 Phase 2 Tc 99m tilmanocept
37 Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) Completed NCT01276236 Phase 2 Maraviroc
38 Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
39 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin
40 Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00001059 Phase 2 Doxorubicin hydrochloride (liposomal);Filgrastim;Bleomycin sulfate;Vincristine sulfate
41 Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma Completed NCT00000996 Phase 2 Doxorubicin hydrochloride
42 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy Completed NCT00000807 Phase 2 Etoposide
43 A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
44 A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA Completed NCT00019123 Phase 2 thalidomide
45 A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma Completed NCT00005931 Phase 2 SU5416
46 Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000687 Phase 2 Interferon alfa-2a;Zidovudine
47 A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
48 A Phase II Study of Liposomal Doxorubicin and Interleukin-12 in AIDS-Associated Kaposi's Sarcoma Followed by Chronic Administration of Interleukin-12 Completed NCT00020449 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
49 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
50 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alitretinoin
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Paclitaxel
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
siltuximab
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi Sarcoma 28

Anatomical Context for Kaposi Sarcoma

Organs/tissues related to Kaposi Sarcoma:

MalaCards : Skin, Lung, Lymph Node, Prostate, Endothelial, Liver, Heart

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 15261)
# Title Authors PMID Year
1
An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. 53 62 57 5
11001912 2000
2
Cloning a human saliva-derived peptide for preventing KSHV transmission. 62 57
22377758 2012
3
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. 62 57
22490805 2012
4
Salivary lactoferrin is recognized by the human herpesvirus-8. 62 57
15955101 2005
5
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. 62 57
15220917 2004
6
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. 62 57
15220918 2004
7
Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998. 62 57
14583765 2003
8
Expression of human herpesvirus 8 in primary pulmonary hypertension. 62 57
13679525 2003
9
Kaposi's sarcoma-associated herpesvirus--the high cost of viral survival. 62 57
13679522 2003
10
Structure of an extracellular gp130 cytokine receptor signaling complex. 62 57
11251120 2001
11
High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. 62 57
9569061 1998
12
Monoclonal origin of multicentric Kaposi's sarcoma lesions. 62 57
9077377 1997
13
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. 62 57
8705863 1996
14
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. 62 57
8705864 1996
15
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. 62 57
7997879 1994
16
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. 62 57
6272109 1981
17
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. 62 57
6975437 1981
18
Opportunistic infections and Kaposi's sarcoma in homosexual men. 62 57
6272112 1981
19
Kaposi's sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. 62 57
7304649 1981
20
Familial Kaposi's sarcoma. 62 57
435392 1979
21
Kaposi's sarcoma in a father and son. 62 57
13788156 1960
22
Biomolecular Fluorescence Complementation Profiling and Artificial Intelligence Structure Prediction of the Kaposi's Sarcoma-Associated Herpesvirus ORF18 and ORF30 Interaction. 62 41
36077046 2022
23
Evaluation of a training intervention to improve cancer care in Zimbabwe: Strategies to Improve Kaposi Sarcoma Outcomes (SIKO), a prospective community-based stepped-wedge cluster randomized trial. 62 41
36028920 2022
24
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 5
17623760 2007
25
Interleukin-6 involvement in brain arteriovenous malformations. 5
16278864 2006
26
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 5
16150725 2005
27
Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. 5
15472205 2004
28
Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. 5
15331795 2004
29
Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. 5
15070960 2004
30
Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. 5
12719374 2003
31
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. 5
12519862 2003
32
The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. 5
12560873 2003
33
The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. 5
11889177 2002
34
Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. 5
10720087 2000
35
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. 5
9769329 1998
36
Combination therapy for pediatric patients with Kasabach-Merritt phenomenon: A single-center retrospective study. 41
36042656 2022
37
Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. 53 62
19690161 2009
38
Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. 53 62
19654515 2009
39
Linear IgA bullous dermatosis induced by interferon-alpha 2a. 53 62
19508467 2009
40
Kaposi's sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists. 53 62
19258523 2009
41
ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. 53 62
19260835 2009
42
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. 53 62
18836096 2009
43
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. 53 62
18566614 2008
44
The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. 53 62
18758494 2008
45
Sirolimus (rapamycin): from the soil of Easter Island to a bright future. 53 62
17583372 2007
46
Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. 53 62
17868650 2007
47
AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? 53 62
17656146 2007
48
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. 53 62
17721110 2007
49
Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. 53 62
16572284 2007
50
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". 53 62
17386117 2007

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL6, IL6-AS1 NG_011640.1:g.4880C>G SNV Risk Factor
14718 rs1800795 GRCh37: 7:22766645-22766645
GRCh38: 7:22727026-22727026

Cosmic variations for Kaposi Sarcoma:

8 (show top 50) (show all 60)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 59
2 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 56
3 COSM98338978 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 56
4 COSM98373331 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 56
5 COSM93554172 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 56
6 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 56
7 COSM92729038 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 56
8 COSM117948203 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 56
9 COSM132326062 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 56
10 COSM91028178 PTPRD soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 56
11 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 56
12 COSM132607215 PTPRD soft tissue,lung,sarcoma,NS c.2912C>T p.A971V 9:8404587-8404587 56
13 COSM102156539 PTPRD soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 56
14 COSM102254463 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 56
15 COSM92957889 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 56
16 COSM102059370 PTPRD soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 56
17 COSM106841030 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 56
18 COSM103461667 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 56
19 COSM110727009 PTCH1 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 56
20 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 56
21 COSM108525670 PTCH1 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 56
22 COSM108470656 PTCH1 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 56
23 COSM98545043 PTCH1 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 56
24 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 56
25 COSM149000769 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 56
26 COSM91788538 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 56
27 COSM102558626 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 56
28 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 56
29 COSM93619977 PBRM1 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 56
30 COSM88073526 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 56
31 COSM102926575 PBRM1 soft tissue,lung,sarcoma,NS c.2879G>A p.R960H 3:52589201-52589201 56
32 COSM104534913 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 56
33 COSM102955053 PBRM1 soft tissue,lung,sarcoma,NS c.2879G>A p.R960H 3:52589201-52589201 56
34 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 56
35 COSM98743623 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 56
36 COSM91962426 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 56
37 COSM134990158 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 56
38 COSM87804075 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 56
39 COSM134990190 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 56
40 COSM91859752 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 56
41 COSM134615012 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 56
42 COSM134614978 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 56
43 COSM87804055 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 56
44 COSM91859771 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 56
45 COSM113328424 HGF soft tissue,lung,sarcoma,NS c.1696G>T p.V566L 7:81706333-81706333 56
46 COSM87850803 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 56
47 COSM151007219 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 56
48 COSM99664612 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 56
49 COSM100583919 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 56
50 COSM118450453 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 56

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 ADA2 FGF2 IFNA1 IFNA2 IL1B IL6
2
Show member pathways
13.76 VEGFA IL6R IL6 IL1B IFNA2 IFNA1
3 13.75 CCL1 CCNK CCR8 FGF2 FGF4 IL6
4
Show member pathways
13.73 VEGFA TNFRSF4 OSM IL6R IL6 IL1B
5
Show member pathways
13.5 VEGFA IL6R IL6 IL1B IFNA2 IFNA1
6
Show member pathways
13.35 TNFRSF4 OSM IL6R IL6 IL1B FGF4
7
Show member pathways
13.34 CASP7 CCL1 CCR8 IFNA1 IFNA2 IL1B
8
Show member pathways
13.18 VEGFA TNFRSF4 OSM IL6ST IL6R IL6
9
Show member pathways
13.13 TNFRSF4 OSM IL6R IL6 IL1B FGF4
10
Show member pathways
12.81 IL6 IL1B IFNA2 IFNA1 CDK6
11 12.66 FGF2 FGF4 IL1B IL6 VEGFA
12
Show member pathways
12.54 FGF2 FGF4 IFNA1 IFNA2 IL1B IL6
13
Show member pathways
12.47 IL6 IL1B IFNA2 IFNA1
14
Show member pathways
12.42 IL6ST FGF4 FGF2 CDK6
15
Show member pathways
12.42 VEGFA OSM IL6R IL6 IFNA2 IFNA1
16
Show member pathways
12.38 IL6 IL1B IFNA2 IFNA1
17
Show member pathways
12.25 IL6ST IL6R IL6 CASP7
18 12.14 VEGFA IL6R IL6 IL1B
19 12.05 VEGFA IL6 FGF4 FGF2
20 12.04 IL6ST IL6R IL6 IL1B FGF2
21 11.92 IL6ST IL6R IL6 IL1B
22
Show member pathways
11.88 IL6ST IL6 IL1B
23 11.87 VEGFA IL6 FGF2 CCR8
24 11.86 IL6 FGF4 FGF2
25
Show member pathways
11.84 IL6ST IL6R IL6
26 11.84 VEGFA IL1B CASP7
27
Show member pathways
11.84 IL6ST IL6R IL6 IL1B
28 11.83 IL6 IFNA2 IFNA1
29 11.75 VEGFA FGF4 FGF2
30 11.73 VEGFA IL6 IL1B IFNA2
31 11.72 IL6 IL1B IFNA2
32 11.68 IL6R IL6 IL1B
33
Show member pathways
11.64 VEGFA IL6 IL1B
34 11.64 IL6 IL1B FGF2
35 11.63 IL6ST IL6R IL6 IL1B
36 11.57 CASP7 IL6 IL6R VEGFA
37
Show member pathways
11.57 VEGFA OSM IL6ST IL6R IL6
38 11.54 VEGFA IL6ST IL6R IL6
39
Show member pathways
11.52 IL6ST IL6R IL6
40 11.48 IL6ST IL6R IL6
41 11.45 VEGFA FGF4 FGF2
42 11.32 IL6 IL6R IL6ST
43 11.26 SLC7A11 IL6 IL1B
44 11.23 VEGFA IL6R IL6 FGF4 FGF2
45 11.2 VEGFA IL6 IL1B IFNA1
46 11.13 VEGFA OSM IL6R IL6 IL1B FGF2
47 11 OSM IL6 IL1B FGF4 FGF2 CCL1
48 11 IL6ST IL6R IL6
49 10.77 IL6 IL1B

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.23 VEGFA OSM IL6ST IL6R IL6 IL1B
2 extracellular space GO:0005615 10.03 ADA2 CASP7 CCL1 FGF2 FGF4 IFNA1
3 ciliary neurotrophic factor receptor complex GO:0070110 9.56 IL6ST IL6R
4 interleukin-6 receptor complex GO:0005896 9.1 IL6ST IL6R IL6

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.38 VEGFA IL6 IL1B FGF4 FGF2 CDK6
2 immune response GO:0006955 10.28 TNFRSF4 OSM IL6 IL1B CCR8 CCL1
3 positive regulation of cell population proliferation GO:0008284 10.22 FGF2 FGF4 IL1B IL6 IL6R IL6ST
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.11 VEGFA OSM IL6R IL6
5 monocyte chemotaxis GO:0002548 10.08 CCL1 IL6 IL6R
6 positive regulation of osteoblast differentiation GO:0045669 10.06 IL6ST IL6R IL6 FGF2
7 positive regulation of MAPK cascade GO:0043410 10.03 VEGFA OSM IL6R IL6 FGF2
8 positive regulation of vascular endothelial growth factor production GO:0010575 10.02 IL6ST IL6 IL1B
9 positive regulation of chemokine production GO:0032722 9.99 IL6R IL6 IL1B
10 positive regulation of interleukin-17 production GO:0032740 9.97 OSM IL6 CCL1
11 cytokine-mediated signaling pathway GO:0019221 9.93 IFNA1 IFNA2 IL1B IL6 IL6R IL6ST
12 T-helper 17 cell lineage commitment GO:0072540 9.92 IL6R IL6
13 oncostatin-M-mediated signaling pathway GO:0038165 9.91 OSM IL6ST
14 chondroblast differentiation GO:0060591 9.88 FGF2 FGF4
15 interleukin-6-mediated signaling pathway GO:0070102 9.88 IL6ST IL6R IL6
16 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.87 IL6R IL6ST
17 positive regulation of acute inflammatory response GO:0002675 9.85 OSM IL6ST IL6
18 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.84 FGF4 FGF2
19 interleukin-11-mediated signaling pathway GO:0038154 9.83 IL6ST IL6R
20 hepatic immune response GO:0002384 9.78 IL6 IL6R
21 positive regulation of epithelial tube formation GO:1905278 9.73 VEGFA FGF2
22 vascular endothelial growth factor production GO:0010573 9.73 IL6R IL6 IL1B
23 positive regulation of cell division GO:0051781 9.65 VEGFA OSM IL1B FGF4 FGF2
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.36 VEGFA OSM IL6ST IL6R IL6 IFNA2

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary neurotrophic factor receptor activity GO:0004897 9.73 IL6ST IL6R
2 growth factor activity GO:0008083 9.73 ADA2 FGF2 FGF4 IL6 OSM VEGFA
3 interleukin-11 binding GO:0019970 9.71 IL6ST IL6R
4 interleukin-11 receptor activity GO:0004921 9.67 IL6ST IL6R
5 interleukin-6 receptor binding GO:0005138 9.63 IL6ST IL6R IL6
6 interleukin-6 binding GO:0019981 9.62 IL6ST IL6R
7 interleukin-6 receptor activity GO:0004915 9.56 IL6ST IL6R
8 cytokine activity GO:0005125 9.5 VEGFA OSM IL6 IL1B IFNA2 IFNA1

Sources for Kaposi Sarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....